Each jurisdiction has its own documentation standards, licensing quirks, and tolerance for ambiguity. This article breaks down what actually counts as an investigational product, the core import/export rules sponsors need to know, where things typically go wrong, and how experienced teams keep shipments moving.
Key Takeaways
- Investigational products (IPs) face tighter customs scrutiny than approved drugs because they lack full marketing authorization in most destinations
- US, EU, and country-specific frameworks each set distinct labeling, licensing, and recordkeeping requirements
- Incomplete documentation drives most customs delays, especially in emerging markets
- Local regulatory liaison support reduces detention risk in low- and middle-income countries (LMICs)
What Is Considered an Investigational Product?
An investigational product is the pharmaceutical form of an active substance or placebo being tested, or used as a reference, in a clinical trial. This includes marketed products when they're reformulated, repackaged, or used for an unapproved indication.
That definition covers more ground than most sponsors initially assume. Under 21 CFR 207.1, regulators distinguish between:
- Active pharmaceutical ingredient (API): the raw ingredient with pharmacological activity
- Investigational drug product: a finished dosage form, not yet commercially approved for the intended use
- Finished commercial drug product: fully approved and marketed
Investigational medical devices, biologics, and comparator products used as controls also fall under the IP umbrella.
Why This Classification Matters for Trade Compliance
Because IPs are unapproved for general commercial distribution, they're technically misbranded or unregistered under standard trade law unless a specific regulatory exemption applies. That exemption is usually tied to an active clinical trial authorization, such as an IND in the US.
Get the classification wrong, and the shipment loses its legal basis for crossing a border at all.
Core Import and Export Rules Sponsors Must Navigate
Most countries permit import of an unapproved investigational drug only under an active trial authorization tied to a specific study and site. In the US, this means an effective IND, with the consignee limited to the sponsor, a qualified investigator, or a designated US agent.
Export gets more complicated. Under 21 CFR 312.110(b), sponsors choose from four distinct pathways:
- Export under an effective IND: every recipient must be an investigator named in the study
- Export to a listed country under FD&C Act Section 802(c): covers the EU/EEA, Australia, Canada, Japan, Israel, New Zealand, Switzerland, and South Africa. No prior FDA approval or IND is required, but foreign-law and recordkeeping conditions still apply
- Export based on qualifying marketing authorization in one of those same listed countries
- First-export certification to FDA, with ongoing conditions on labeling, cGMP, and foreign use
Beyond the pathway itself, three compliance details trip up sponsors repeatedly:
- Labeling: every immediate package must carry the statement "Caution: New Drug — Limited by Federal (or United States) law to investigational use"
- Recordkeeping: document investigator, date, quantity, and batch/code for each shipment, and retain those records for two years past marketing approval or study discontinuation
- Comparators and ancillary supplies: placebos and comparator drugs often lack IND coverage yet still require full customs clearance. Don't assume they're exempt because they're not the active study drug
Customs classification and licensing requirements diverge sharply across the US, EU, Middle East, and Asia-Pacific. A shipment that clears smoothly in Germany can sit for weeks in a market with less predictable customs processing. That variability is the terrain DRK Research Solutions' regulatory teams navigate daily across Europe, the Middle East, Asia, Africa, and the Americas.
Common Import and Export Challenges in Multi-Regional Trials
Documentation inconsistency across sites is the most common culprit behind customs delays. A shipment description that doesn't match the invoice, or a consignee name that doesn't align with the trial authorization, gives customs a reason to hold the box.
Other recurring friction points:
- Misaligned import permits, controlled substance licenses, and health ministry approvals that rarely fit one global protocol
- Extended customs holds that push biologics and cell/gene therapies past validated shipping windows
- Missing "investigational use only" language or IND/CTA references that make shipments prime detention candidates
Regulatory Fragmentation Across LMICs and Emerging Markets
Low- and middle-income countries often run less predictable customs processes than mature regulatory markets. Import rules can vary not just country to country, but port to port. Local regulatory liaison support is often essential to keep shipments moving and avoid prolonged detentions.
Cold Chain, Packaging, and Logistics Considerations
Biologics and cell/gene therapies carry real stability risk when customs holds run long. FDA's own biologics stability guidance calls for defined storage conditions and real-time stability data, not a generic temperature range applied across every SOP.
Practical safeguards include:
- Validated shipping systems with data loggers that flag temperature excursions in transit
- Pre-clearance coordination with customs brokers and local logistics partners to shrink dwell time at ports of entry
- Pre-positioning stock where mechanisms similar to the US Pre-Launch Activities Importation Request (PLAIR) exist, reducing last-minute import scrambles
One important caveat: PLAIR itself isn't a substitute for IND-linked import strategy. It's a narrow pathway for finished dosage forms pending an anticipated marketing application, and FDA generally expects PLAIR-imported product to be detained and reconditioned under the policy, not released for immediate trial use.
Strategies to Mitigate Import/Export Risks in Global Trials
The sponsors who avoid customs headaches tend to do the same few things early, not after a shipment gets stuck.
- Engage regulatory and customs experts during trial design — map country-specific import/export requirements before a single site activates
- Build a centralized documentation dossier — IND/CTA numbers, labeling templates, certificates of analysis, all accessible to every site and broker involved
- Partner with a CRO that has local regulatory proficiency — cover every region your trial touches
- Maintain contingency stock and backup shipment routes — protect time-sensitive or high-value IPs
This is where a global CRO partner makes the difference. DRK Research Solutions operates across Europe, the Middle East, Asia, Africa, and the Americas, pairing that footprint with local proficiency so compliance plans become shipments that clear customs on schedule.
For sponsors running MRCT sites across a dozen jurisdictions, one partner coordinating regulatory documentation and clinical supply logistics means fewer handoffs and fewer places for things to fall through.
Frequently Asked Questions
What is considered an investigational product?
An investigational product is any unapproved drug, biologic, or device (including comparators and placebos) used in a clinical trial under a regulatory authorization like an IND or CTA. Marketed products used off-label or reformulated for a trial also qualify.
What are the rules for import and export of investigational products?
Investigational products generally require trial-specific authorization, correct investigational-use labeling, and compliance with the destination country's import laws. Sponsors must also maintain detailed shipment and disposition records for regulatory review.
Do investigational products need FDA approval before export from the US?
No. Full approval isn't required, but exporters must satisfy one of the exemptions under FD&C Act Section 802 or the four mechanisms in 21 CFR 312.110(b).
How long does customs clearance typically take for investigational drugs?
Timelines vary significantly by country, documentation completeness, and local customs practices. There's no universal benchmark, but proactive pre-clearance and consistent paperwork reduce delay risk, per FDA-aligned shipping guidance.
Can investigational products be shipped to countries without an established regulatory pathway?
Yes, but sponsors typically need either a written FDA request or a local import permit when no listed-country pathway applies. This route requires more lead time and closer coordination with destination authorities.
Who is responsible for ensuring customs compliance in a multi-regional trial?
Sponsors hold ultimate responsibility but typically delegate day-to-day customs compliance to CROs and customs brokers with local regulatory expertise. Clear accountability at each site prevents documentation gaps.
